Isofol invites to an informational meeting on January 30 prior to extraordinary general meeting
GOTHENBURG, Sweden, January 20, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), yesterday called shareholders to an extraordinary general meeting on February 13. Isofol invites shareholders, investors, analysts, and media to an audiocast with a subsequent question and answer session on January 30, 2023.
In conjunction with the extraordinary general meeting on February 13, Isofol invites shareholders, investors, analysts and the media to an informational meeting via audiocast on January 30 at 3 p.m. At the informational meeting the board of directors will present the background to the proposal for a decision on dividends and liquidation of the company and will include a question and answer session.
For information about Isofol’s decision to call shareholders to an extraordinary general meeting and proposal for dividends and liquidation of the company, please see the press release issued on January 19.
The meeting will be led by Isofol's chairman of the board Jan Törnell and CEO Ulf Jungnelius. CMO Roger Tell and CFO Gustaf Albèrt will also be available to answer questions. The presentation will be held in Swedish.
Date and time
January 30, 2023, 15:00-17:00 p.m. CET
Link to audiocast
If you wish to participate via the web and ask written questions, please use the link below:
https://ir.financialhearings.com/isofol-medical-2023
Teleconference
If you wish to participate via teleconference, please register using the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference:
https://conference.financialhearings.com/teleconference/?id=5001902
The presentation will also be available on Isofol’s website after it is broadcast:
https://isofolmedical.com/company-presentations/
For further information, please contact
Isofol Medical AB (publ)
Jan Törnell, Chairman of the board
E-mail: jan.tornell@innoext.se
Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Phone: +46 (0) 709 16 89 55
The information was submitted for publication, through the agency of the contact person set out above, at 16:45 CET on January 20, 2023.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical-stage biotechnology company that has focused its operations on developing and improving the current standard treatment for patients suffering from cancer by increasing treatment efficacy through the use of cytostatics. Isofol’s ambition was to develop a drug for first-line treatment of advanced colorectal cancer (mCRC), thereby seeking to improve the current clinical practice by realizing the full strength of 5-FU with the addition of arfolitixorin. Isofol has an exclusive global licensing agreement with Merck & Cie in Schaffhausen, Switzerland, to develop and commercialize arfolitixorin in oncology. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.